These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
646 related articles for article (PubMed ID: 37515187)
1. SARS-CoV-2 Spike Protein Is Capable of Inducing Cell-Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies. Reuter N; Chen X; Kropff B; Peter AS; Britt WJ; Mach M; Überla K; Thomas M Viruses; 2023 Jul; 15(7):. PubMed ID: 37515187 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation. Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling. Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner. Lavie M; Dubuisson J; Belouzard S J Virol; 2022 Jul; 96(13):e0047422. PubMed ID: 35678602 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W Viruses; 2021 Dec; 13(12):. PubMed ID: 34960755 [TBL] [Abstract][Full Text] [Related]
11. A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding. Spelios MG; Capanelli JM; Li AW Immunol Lett; 2022 Feb; 242():1-7. PubMed ID: 35007661 [TBL] [Abstract][Full Text] [Related]
12. Structural basis of severe acute respiratory syndrome coronavirus 2 infection. Ge J; Zhang S; Zhang L; Wang X Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors. Palla SR; Li CW; Chao TL; Lo HV; Liu JJ; Pan MY; Chiu YT; Lin WC; Hu CW; Yang CM; Chen YY; Fang JT; Lin SW; Lin YT; Lin HC; Kuo CJ; Wang LH; Chang SY; Liang PH Antiviral Res; 2023 Nov; 219():105735. PubMed ID: 37858764 [TBL] [Abstract][Full Text] [Related]
14. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663 [TBL] [Abstract][Full Text] [Related]
15. Structural and functional modelling of SARS-CoV-2 entry in animal models. Brooke GN; Prischi F Sci Rep; 2020 Sep; 10(1):15917. PubMed ID: 32985513 [TBL] [Abstract][Full Text] [Related]
16. A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS-CoV-2 Spike-Mediated Viral Invasion. Wu M; Li W; Lin S; Fan J; Cui L; Xiang Y; Li K; Tang L; Duan Y; Chen Z; Yang F; Shui W; Lu G; Lai Y Adv Sci (Weinh); 2023 Oct; 10(28):e2301478. PubMed ID: 37590389 [TBL] [Abstract][Full Text] [Related]
17. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM Viruses; 2022 May; 14(5):. PubMed ID: 35632769 [TBL] [Abstract][Full Text] [Related]
18. ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin. Partridge LJ; Urwin L; Nicklin MJH; James DC; Green LR; Monk PN Cells; 2021 Jun; 10(6):. PubMed ID: 34200372 [TBL] [Abstract][Full Text] [Related]
19. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
20. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]